Supplementary Table 4.docx (27.05 kB)
Supplementary Table 4: Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase 3 safety study
dataset
posted on 2021-11-18, 09:13 authored by Shin-ichi Konno, Takuya Nikaido, John D Markman, Makoto Ohta, Toshiya Machida, Naoki Isogawa, Hiroki Yoshimatsu, Lars Viktrup, Mark T Brown, Christine R West, Kenneth M Verburg|
Supplementary Table 4. Tanezumab for Chronic Low Back Pain: A Long-term, Randomized, Celecoxib-Controlled, Japanese, Phase 3, Safety Study Summary of TEAEs of possible decreased sympathetic function through week 80 (treatment + follow-up periods) |
